STI571 (Gleevec™) as a paradigm for cancer therapy

BJ Druker - Trends in molecular medicine, 2002 - cell.com
BJ Druker
Trends in molecular medicine, 2002cell.com
STI571 (Gleevec™, imatinib mesylate) exemplifies the successful development of a
rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This
article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous
leukemia and the steps in the development of an agent to inactivate this abnormality. Issues
related to clinical trials of molecularly targeted agents are discussed, including dose and
patient selection and possible mechanisms of resistance to STI571. Finally, the potential use …
Abstract
STI571 (Gleevec™, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection and possible mechanisms of resistance to STI571. Finally, the potential use of STI571 with different tumors and the translation of this paradigm to other malignancies are explored.
cell.com